Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date

NewTimeSpace News：iFinD data shows that CSOP Hang Seng Biotech ETF (3174.HK) closed at HKD 4.026 on October 6, up 3.18% (HKD 0.124), after opening at HKD 3.960 and trading between HKD 3.960 and HKD 4.030, with an average price of HKD 4.017 and an amplitude of 1.79%; full-day turnover was 430,000 shares worth HKD 1.7362 million for a turnover ratio of 0.17%, and the closing order imbalance ratio was -39.16% with a bid-ask gap of -112, indicating thin sell-side quotes. Fund assets stood at about HKD 1.023 billion with roughly 255.7 million units issued and a unit NAV of HKD 4.003 (NAV, units and assets are all as of September 30 and are subject to reporting lags).

On performance, the fund returned 17.93% year-to-date, 20.54% over 60 days, 9.58% over 120 days, 8.28% over 20 days and 5.84% over 5 days, while its 250-day return was -0.74%, a marked divergence between long and short horizons: its NAV rose 75.81% in 2025 (against +74.99% for the index) but fell for three consecutive years in 2022-2024 (-27.35%, -30.65% and -20.06% respectively), reflecting a full down-cycle for the biotech sector. Constituents rallied across the board on October 6: GENSCRIPT BIO rose 6.88% to HKD 48.78, a record high, WUXI BIO gained 4.51%, AKESO 4.06% and SBP GROUP 4.05%, while ZAI LAB and ASCENTAGE climbed more than 8%.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.